Early drills results promise big things for this gold stock

From JuniorStocks | Ad

This company's land investments have put them into the pole position for the next big gold discovery. The one stock to watch out for.

Click to Find out More

ITCI Insider Trading (Intra-Cellular Therapies)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 18.20%

Insider Buying (Last 12 Months): $2,054,880.00

Insider Selling (Last 12 Months): $13,540,321.06

Intra-Cellular Therapies Insider Trading History Chart

Intra-Cellular Therapies Share Price & Price History

^$33.43

▲ +1.05 (3.24%)

As of 05/6/2021 01:00 AM ET

Days: 30 | 90 | 365

Cannabis Companies are Soaring Again

From Wall Street Rebel | Ad

Pot stocks are riding a massive election high right now, and it's not too late to take advantage of it. There are still rumblings about this medical cannabis disruptor that has a production cost of 50% less than their competitors….

And that means more profits.

Don't Wait to Discover this Company

Intra-Cellular Therapies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/19/2021	Lawrence J Hineline	CFO	Sell	10,442	$39.23	$409,639.66	10,442
2/19/2021	Mark Neumann	EVP	Sell	5,184	$39.22	$203,316.48	50,523
2/19/2021	Sharon Mates	CEO	Sell	27,847	$39.23	$1,092,437.81	1,161,239
2/19/2021	Suresh K Durgam	Insider	Sell	2,734	$39.25	$107,309.50	25,838
1/11/2021	Lawrence J. Hineline	CFO	Sell	19,638	$32.02	$628,808.76
1/11/2021	Mark Neumann	EVP	Sell	9,684	$32.02	$310,081.68	49,068
1/11/2021	Sharon Mates	CEO	Sell	41,896	$32.01	$1,341,090.96	1,175,288
1/11/2021	Suresh K Durgam	Insider	Sell	4,367	$32.12	$140,268.04	21,851
1/4/2021	Lawrence J Hineline	CFO	Sell	15,810	$31.31	$495,011.10
1/4/2021	Michael Halstead	EVP	Sell	16,160	$31.30	$505,808.00
1/4/2021	Sharon Mates	CEO	Sell	48,341	$31.30	$1,513,073.30
11/17/2020	Michael Halstead	EVP	Sell	79,425	$27.62	$2,193,718.50	79,425
11/11/2020	Lawrence J Hineline	CFO	Sell	28,034	$25.41	$712,343.94	18,034
11/4/2020	Sharon Mates	CEO	Sell	50,000	$25.00	$1,250,000.00	1,163,392
10/16/2020	Mark Neumann	EVP	Sell	6,792	$26.80	$182,025.60	34,912
9/14/2020	Christopher D Alafi	Director	Buy	49,500	$29.60	$1,465,200.00	345,223
9/11/2020	Christopher D Alafi	Director	Buy	21,000	$28.08	$589,680.00
9/9/2020	Lawrence J Hineline	CFO	Sell	41,983	$31.14	$1,307,350.62	50,017
5/13/2020	Joel S Marcus	Director	Sell	7,297	$20.63	$150,537.11	14,374
5/11/2020	Joel S Marcus	Director	Sell	50,000	$19.95	$997,500.00	14,374
1/9/2020	Andrew Satlin	EVP	Sell	11,573	$26.16	$302,749.68	22,911
1/9/2020	Lawrence J Hineline	CFO	Sell	19,638	$26.16	$513,730.08	18,800
1/9/2020	Sharon Mates	CEO	Sell	41,895	$26.16	$1,095,973.20	1,204,707
1/6/2020	Michael Halstead	EVP	Sell	21,458	$30.34	$651,035.72	17,704
1/6/2020	Sharon Mates	CEO	Sell	45,598	$30.28	$1,380,707.44	1,182,366
1/2/2020	Michael Halstead	EVP	Sell	7,807	$32.43	$253,181.01	7,998
1/2/2020	Sharon Mates	CEO	Sell	17,478	$32.45	$567,161.10	1,156,185
10/16/2019	Mark Neumann	EVP	Sell	6,774	$8.25	$55,885.50	13,448
9/10/2019	Christopher D Alafi	Director	Buy	485,000	$10.26	$4,976,100.00	341,223
8/30/2019	Christopher D Alafi	Director	Buy	125,000	$8.52	$1,065,000.00	341,223
6/12/2019	Christopher D Alafi	Director	Buy	170,000	$11.73	$1,994,100.00	750,106
5/14/2019	Christopher D Alafi	Director	Buy	100,000	$12.56	$1,256,000.00	750,106
2/27/2019	Lawrence J Hineline	CFO	Sell	1,000	$15.00	$15,000.00	25,832
1/7/2019	Kimberly E Vanover	SVP	Sell	592	$12.29	$7,275.68	37,224
1/7/2019	Michael Halstead	EVP	Sell	3,108	$12.42	$38,601.36	24,757
1/7/2019	Sharon Mates	CEO	Sell	6,604	$12.43	$82,087.72	1,190,909
1/4/2019	Kimberly E Vanover	SVP	Sell	9,564	$11.47	$109,699.08	37,224
1/4/2019	Michael Halstead	EVP	Sell	21,458	$11.46	$245,908.68	24,757
1/4/2019	Sharon Mates	CEO	Sell	45,598	$11.45	$522,097.10	1,190,909
1/2/2019	Lawrence J Hineline	SVP	Sell	7,807	$11.09	$86,579.63	24,839
1/2/2019	Sharon Mates	CEO	Sell	17,478	$11.09	$193,831.02	1,156,185
12/6/2018	Robert E Davis	SVP	Sell	899	$13.53	$12,163.47	31,155
11/12/2018	Joel S Marcus	Director	Sell	32,000	$18.17	$581,440.00	21,671
11/9/2018	Joel S Marcus	Director	Sell	25,000	$18.24	$456,000.00	21,671

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

79.10% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intra-Cellular Therapies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/6/2021	Arizona State Retirement System	21,001	$0.71M	0.0%	+1.9%	0.026%
5/6/2021	Blueshift Asset Management LLC	13,535	$0.46M	0.0%	N/A	0.017%
5/6/2021	Rhumbline Advisers	94,026	$3.19M	0.0%	-7.5%	0.116%
5/6/2021	Alliancebernstein L.P.	95,810	$3.25M	0.0%	+1.3%	0.118%
5/6/2021	Altium Capital Management LP	88,326	$3M	0.8%	-42.4%	0.109%
5/6/2021	M&T Bank Corp	7,015	$0.24M	0.0%	-36.0%	0.009%
5/4/2021	Asset Management Corp IL ADV	21,685	$0.74M	0.3%	+32.3%	0.027%
5/3/2021	The Manufacturers Life Insurance Company	35,990	$1.22M	0.0%	-6.4%	0.044%
5/3/2021	Zurcher Kantonalbank Zurich Cantonalbank	9,781	$0.33M	0.0%	+5.2%	0.012%
5/3/2021	Avestar Capital LLC	21,323	$0.73M	0.2%	N/A	0.026%
4/27/2021	State of New Jersey Common Pension Fund D	63,743	$2.16M	0.0%	-22.4%	0.079%
4/26/2021	Assenagon Asset Management S.A.	208,301	$7.07M	0.0%	+2.1%	0.257%
4/15/2021	First Midwest Bank Trust Division	92,504	$3.14M	0.4%	-31.4%	0.114%
3/12/2021	DekaBank Deutsche Girozentrale	30,900	$0.95M	0.0%	-4.6%	0.038%
3/10/2021	Los Angeles Capital Management LLC	9,132	$0.29M	0.0%	N/A	0.011%
3/8/2021	B. Metzler seel. Sohn & Co. Holding AG	21,623	$0.70M	0.0%	N/A	0.027%
3/8/2021	Dimensional Fund Advisors LP	1,177,771	$37.45M	0.0%	-23.9%	1.456%
3/2/2021	Norges Bank	527,281	$16.77M	0.0%	N/A	0.658%
3/1/2021	UBS Asset Management Americas Inc.	67,644	$2.15M	0.0%	+30.8%	0.084%
2/25/2021	Dimensional Fund Advisors LP	1,177,771	$37.45M	0.0%	-23.9%	1.469%
2/25/2021	Hsbc Holdings PLC	9,088	$0.29M	0.0%	N/A	0.011%
2/24/2021	Alyeska Investment Group L.P.	218,473	$6.95M	0.1%	-60.7%	0.273%
2/24/2021	EMC Capital Management	25,848	$0.82M	0.6%	N/A	0.032%
2/23/2021	Principal Financial Group Inc.	22,892	$0.73M	0.0%	+66.2%	0.029%
2/19/2021	International Biotechnology Trust PLC	79,456	$2.53M	0.7%	+220.4%	0.099%
2/18/2021	Verition Fund Management LLC	67,457	$2.15M	0.0%	N/A	0.084%
2/16/2021	Walleye Capital LLC	65,400	$2.08M	0.1%	N/A	0.082%
2/16/2021	Silverarc Capital Management LLC	200,000	$6.36M	3.7%	N/A	0.250%
2/16/2021	Squarepoint Ops LLC	10,728	$0.34M	0.0%	-75.9%	0.013%
2/16/2021	Alyeska Investment Group L.P.	218,473	$6.95M	0.1%	-60.7%	0.273%
2/16/2021	Morgan Stanley	480,343	$15.28M	0.0%	-5.3%	0.599%
2/16/2021	Neo Ivy Capital Management	3,495	$0.11M	0.1%	+300.8%	0.004%
2/16/2021	Nuveen Asset Management LLC	778,319	$24.75M	0.0%	-1.6%	0.971%
2/16/2021	Pier Capital LLC	190,833	$6.07M	0.6%	N/A	0.238%
2/16/2021	Price T Rowe Associates Inc. MD	31,490	$1M	0.0%	-90.0%	0.039%
2/16/2021	Virginia Retirement Systems ET AL	6,800	$0.22M	0.0%	N/A	0.008%
2/16/2021	Schroder Investment Management Group	1,313,026	$41.75M	0.1%	+31.3%	1.638%
2/16/2021	Gyon Technologies Capital Management LP	42,781	$1.36M	0.5%	N/A	0.053%
2/16/2021	Janus Henderson Group PLC	46,783	$1.49M	0.0%	N/A	0.058%
2/16/2021	Charles Schwab Investment Management Inc.	457,962	$14.56M	0.0%	+3.3%	0.571%
2/13/2021	American International Group Inc.	38,568	$1.23M	0.0%	-1.3%	0.048%
2/12/2021	Stifel Financial Corp	30,733	$0.98M	0.0%	-4.6%	0.038%
2/12/2021	DCF Advisers LLC	424,500	$13.50M	5.6%	-0.6%	0.530%
2/12/2021	Vantage Consulting Group Inc	226,670	$7.21M	0.6%	N/A	0.283%
2/12/2021	Penserra Capital Management LLC	1,840	$58K	0.0%	+220.6%	0.002%
2/12/2021	Amalgamated Bank	7,496	$0.24M	0.0%	N/A	0.009%
2/12/2021	Public Employees Retirement System of Ohio	95,158	$3.03M	0.0%	+17.1%	0.119%
2/12/2021	The Manufacturers Life Insurance Company	38,432	$1.22M	0.0%	+6.4%	0.048%
2/12/2021	Credit Suisse AG	89,272	$2.84M	0.0%	+63.5%	0.111%
2/12/2021	Jaffetilchin Investment Partners LLC	43,929	$1.40M	0.2%	N/A	0.055%
2/12/2021	Virtus ETF Advisers LLC	24,085	$0.77M	0.3%	+57.4%	0.030%
2/12/2021	M&T Bank Corp	10,953	$0.35M	0.0%	-45.7%	0.014%
2/11/2021	Northern Trust Corp	954,551	$30.35M	0.0%	-1.7%	1.191%
2/11/2021	Barclays PLC	156,730	$4.98M	0.0%	+9.5%	0.196%
2/11/2021	Citigroup Inc.	53,425	$1.70M	0.0%	+367.3%	0.067%
2/11/2021	Asymmetry Capital Management L.P.	130,654	$4.16M	1.9%	N/A	0.163%
2/11/2021	Nicholas Investment Partners LP	390,289	$12.41M	1.0%	-14.7%	0.487%
2/10/2021	Rhumbline Advisers	101,643	$3.23M	0.0%	+13.6%	0.127%
2/10/2021	Clearbridge Investments LLC	621,745	$19.77M	0.0%	-3.8%	0.776%
2/9/2021	Wells Fargo & Company MN	111,347	$3.54M	0.0%	+32.0%	0.139%
2/9/2021	Advisory Services Network LLC	775	$25K	0.0%	-55.1%	0.001%
2/9/2021	Bank of New York Mellon Corp	292,312	$9.30M	0.0%	-6.2%	0.365%
2/9/2021	ProShare Advisors LLC	27,061	$0.86M	0.0%	+43.5%	0.034%
2/8/2021	New York State Common Retirement Fund	79,380	$2.52M	0.0%	+8.1%	0.099%
2/5/2021	BlackRock Inc.	5,898,568	$187.58M	0.0%	+11.9%	7.359%
2/5/2021	Y Intercept Hong Kong Ltd	10,453	$0.34M	0.1%	N/A	0.013%
2/5/2021	CM Management LLC	25,000	$0.80M	0.7%	N/A	0.031%
2/5/2021	SG Americas Securities LLC	128,780	$4.10M	0.0%	+56.7%	0.161%
2/4/2021	Foundry Partners LLC	31,179	$0.99M	0.0%	N/A	0.039%
2/4/2021	State of Wisconsin Investment Board	103,300	$3.29M	0.0%	+2.3%	0.129%
2/3/2021	State of New Jersey Common Pension Fund D	82,133	$2.61M	0.0%	N/A	0.102%
2/2/2021	California Public Employees Retirement System	147,265	$4.68M	0.0%	+15.1%	0.184%
2/1/2021	Assenagon Asset Management S.A.	203,988	$6.49M	0.0%	-57.1%	0.254%
1/29/2021	Asset Management Corp IL ADV	16,385	$0.55M	0.3%	-37.7%	0.020%
1/28/2021	Arizona State Retirement System	20,612	$0.66M	0.0%	+14.2%	0.026%
1/28/2021	Zurcher Kantonalbank Zurich Cantonalbank	9,296	$0.30M	0.0%	+23.0%	0.012%
1/27/2021	Penbrook Management LLC	4,000	$0.13M	0.1%	N/A	0.005%
1/26/2021	Pinnacle Associates Ltd.	247,194	$7.86M	0.2%	-6.4%	0.308%
1/25/2021	Nisa Investment Advisors LLC	8,700	$0.28M	0.0%	+16.4%	0.011%
1/22/2021	Candriam Luxembourg S.C.A.	456,022	$14.50M	0.1%	+6.1%	0.569%
1/19/2021	Rhenman & Partners Asset Management AB	500,000	$15.90M	1.3%	+5.3%	0.624%
1/14/2021	First Midwest Bank Trust Division	134,891	$4.29M	0.6%	-41.4%	0.168%
12/14/2020	Strs Ohio	2,900	$74K	0.0%	-40.8%	0.004%
12/4/2020	Sei Investments Co.	26,533	$0.68M	0.0%	+134.3%	0.033%
12/1/2020	International Biotechnology Trust PLC	24,800	$0.64M	0.2%	+7.8%	0.031%
11/17/2020	Nantahala Capital Management LLC	174,461	$4.48M	0.1%	N/A	0.218%
11/17/2020	Public Employees Retirement System of Ohio	81,275	$2.09M	0.0%	+26.8%	0.101%
11/17/2020	Voloridge Investment Management LLC	29,078	$0.75M	0.0%	N/A	0.036%
11/17/2020	California State Teachers Retirement System	98,925	$2.54M	0.0%	+19.3%	0.123%
11/17/2020	Polar Capital LLP	150,000	$3.85M	0.0%	N/A	0.187%
11/16/2020	Point72 Hong Kong Ltd	2,284	$59K	0.0%	N/A	0.003%
11/16/2020	Cubist Systematic Strategies LLC	29,820	$0.77M	0.0%	+238.9%	0.037%
11/16/2020	Point72 Asset Management L.P.	555,643	$14.26M	0.1%	N/A	0.693%
11/16/2020	AQR Capital Management LLC	51,648	$1.33M	0.0%	-16.6%	0.064%
11/16/2020	Squarepoint Ops LLC	44,474	$1.14M	0.0%	N/A	0.055%
11/16/2020	Samlyn Capital LLC	1,732,365	$44.45M	0.8%	-4.5%	2.161%
11/16/2020	ExodusPoint Capital Management LP	84,027	$2.16M	0.0%	N/A	0.105%
11/16/2020	Polar Capital LLP	150,000	$3.85M	0.0%	N/A	0.187%
11/16/2020	Amia Capital LLP	19,972	$0.51M	0.6%	-22.0%	0.025%
11/13/2020	Morgan Stanley	507,421	$13.02M	0.0%	-0.2%	0.633%

Data available starting January 2016

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Today's Range

Now: $33.43

$31.40

$33.51

50 Day Range

MA: $32.69

$29.30

$35.94

52 Week Range

Now: $33.43

$16.90

$40.01

Volume

333,763 shs

Average Volume

590,988 shs

Market Capitalization

$2.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?

Intra-Cellular Therapies' top insider shareholders include:

Sharon Mates (CEO)
Christopher D Alafi (Director)
Michael Halstead (EVP)
Mark Neumann (EVP)
Lawrence J Hineline (CFO)
Suresh K Durgam (Insider)
Andrew Satlin (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)

Who are the major institutional investors of Intra-Cellular Therapies?

Intra-Cellular Therapies' top institutional shareholders include:

Assenagon Asset Management S.A. — 0.26%
Alliancebernstein L.P. — 0.12%
Rhumbline Advisers — 0.12%
First Midwest Bank Trust Division — 0.11%
Altium Capital Management LP — 0.11%
State of New Jersey Common Pension Fund D — 0.08%

Which institutional investors are selling Intra-Cellular Therapies stock?

In the previous quarter, ITCI stock was sold by these institutional investors:

Altium Capital Management LP
First Midwest Bank Trust Division
State of New Jersey Common Pension Fund D
Rhumbline Advisers
M&T Bank Corp
The Manufacturers Life Insurance Company

During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:

Sharon Mates (CEO)
Christopher D Alafi (Director)
Michael Halstead (EVP)
Mark Neumann (EVP)
Lawrence J Hineline (CFO)
Suresh K Durgam (Insider)
Andrew Satlin (EVP)

Which institutional investors are buying Intra-Cellular Therapies stock?

During the last quarter, ITCI stock was acquired by institutional investors including:

Avestar Capital LLC
Blueshift Asset Management LLC
Asset Management Corp IL ADV
Assenagon Asset Management S.A.
Alliancebernstein L.P.
Zurcher Kantonalbank Zurich Cantonalbank
Arizona State Retirement System

This tech company just released their 2020 financial statements

From JuniorStocks | Ad

You don't want to miss this